CN101646452A - 使用益生菌降低剖宫产婴儿的腹泻发作 - Google Patents
使用益生菌降低剖宫产婴儿的腹泻发作 Download PDFInfo
- Publication number
- CN101646452A CN101646452A CN200880010523A CN200880010523A CN101646452A CN 101646452 A CN101646452 A CN 101646452A CN 200880010523 A CN200880010523 A CN 200880010523A CN 200880010523 A CN200880010523 A CN 200880010523A CN 101646452 A CN101646452 A CN 101646452A
- Authority
- CN
- China
- Prior art keywords
- purposes
- oligosaccharides
- gal
- 4glc
- 3gal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 28
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 28
- 206010012735 Diarrhoea Diseases 0.000 title abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 54
- 241000894006 Bacteria Species 0.000 claims abstract description 22
- 230000000529 probiotic effect Effects 0.000 claims abstract description 22
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 229920001542 oligosaccharide Polymers 0.000 claims description 57
- 150000002482 oligosaccharides Chemical class 0.000 claims description 56
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 claims description 26
- 235000013350 formula milk Nutrition 0.000 claims description 21
- 230000007935 neutral effect Effects 0.000 claims description 12
- 235000015097 nutrients Nutrition 0.000 claims description 12
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 11
- 241000186660 Lactobacillus Species 0.000 claims description 9
- 241000186012 Bifidobacterium breve Species 0.000 claims description 8
- 229940039696 lactobacillus Drugs 0.000 claims description 8
- 241000186000 Bifidobacterium Species 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 5
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 claims description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 4
- 230000003203 everyday effect Effects 0.000 claims description 4
- 229940060155 neuac Drugs 0.000 claims description 4
- CERZMXAJYMMUDR-UHFFFAOYSA-N neuraminic acid Natural products NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO CERZMXAJYMMUDR-UHFFFAOYSA-N 0.000 claims description 4
- 241001608472 Bifidobacterium longum Species 0.000 claims description 3
- 208000019637 Infantile Diarrhea Diseases 0.000 claims description 3
- 241000186840 Lactobacillus fermentum Species 0.000 claims description 3
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 3
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 3
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 claims 1
- IXWNIYCPCRHGAE-DFZOHVKFSA-N alpha-D-GalNAc-(1->3)-D-Gal Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O IXWNIYCPCRHGAE-DFZOHVKFSA-N 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 229940088594 vitamin Drugs 0.000 description 15
- 229930003231 vitamin Natural products 0.000 description 15
- 235000013343 vitamin Nutrition 0.000 description 15
- 239000011782 vitamin Substances 0.000 description 15
- 150000003722 vitamin derivatives Chemical class 0.000 description 14
- 230000000813 microbial effect Effects 0.000 description 11
- 210000000481 breast Anatomy 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 description 9
- 239000011707 mineral Substances 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000003995 emulsifying agent Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 229930182830 galactose Natural products 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 235000013406 prebiotics Nutrition 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 125000003047 N-acetyl group Chemical group 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 235000020244 animal milk Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 3
- 229940107187 fructooligosaccharide Drugs 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 238000006384 oligomerization reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241001112696 Clostridia Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-BKJPEWSUSA-N N-acetyl-D-hexosamine Chemical compound CC(=O)NC1C(O)O[C@H](CO)C(O)C1O OVRNDRQMDRJTHS-BKJPEWSUSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- -1 antiseptic Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000007366 host health Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- SECPZKHBENQXJG-FPLPWBNLSA-N (Z)-Palmitoleic acid Natural products CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N 3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 229920001732 Lignosulfonate Polymers 0.000 description 1
- 239000004117 Lignosulphonate Substances 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 description 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 102000003838 Sialyltransferases Human genes 0.000 description 1
- 108090000141 Sialyltransferases Proteins 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940071604 biogaia Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012628 flowing agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 150000008272 galactosaminides Chemical class 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 235000019357 lignosulphonate Nutrition 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pediatric Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
益生菌在制备用以预防或治疗剖宫产婴儿腹泻的药物或治疗性营养组合物中的用途。
Description
发明领域
本发明涉及对剖宫产婴儿施用益生菌以降低婴儿期的腹泻发作。
发明背景
在婴儿即将出生时,其胃肠道可以认为是无菌的。在正常的出生过程中,婴儿胃肠道遇到了来自母亲消化道、皮肤和环境的细菌并开始建群。对于健康、顺产、母乳喂养的年龄在2-4周的婴儿,可以认为是此年龄组最佳微生物群的粪便微生物群以双歧杆菌菌种为主,还包括一些乳杆菌菌种和少量的类杆菌,如脆弱类杆菌(Bacteriodes fragilis)菌种,排斥着潜在的病原体如梭菌(Clostridia)。大约在2岁断奶后,开始建成类似成人模式的肠道微生物群模式。
应该注意的是,在健康、顺产、母乳喂养的婴儿中,形成微生物基础的双歧杆菌占婴儿肠道全部细菌的60-90%。母乳喂养也可以促进肠屏障发展,其与占主导的双歧杆菌一起使得所摄取营养的吸收增强,从而增强营养的利用。
等人研究了剖宫产健康婴儿的粪便微生物群,并将其与顺产婴儿可比较的组进行对比。他们的结论是剖宫产婴儿的肠道菌群可能被扰乱至出生后的六个月。他们特别指出,剖宫产组中双歧杆菌和乳杆菌的建群速度分别要在一个月和十天后才能达到顺产组中的建群速度。(等人,“Fecal Microflora in Heathy Infants Born byDifferent Methods of Delivery:Permanent Changes in Intestinal FloraAfter Cesarean Delivery”,Journal of Pediatric Gastroenterology andNutrition,28:19-25)。
其他研究者认为,这种延迟的/异常的建群可能对婴儿后续的发展造成特定的后果,并且将这些后果与肠道菌群的差异联系起来。例如Laubereau等人发现剖宫产婴儿比顺产婴儿有更大的腹泻风险。
对于所有婴儿均推荐母乳喂养。但是,在一些情况下,由于医学原因或母亲选择不进行母乳喂养,母乳喂养是不够或不成功的。针对这些情况开发了婴儿配方。
近来,某些细菌菌株引起了人们很大的注意,因为已发现如果这些菌株被摄入就表现出对人类有价值的性质。特别是,已经发现乳杆菌属和双歧杆菌属的特定菌株能够在肠建群,能够减少病原菌附着肠上皮的能力,具有免疫调节效果并有助于维持健康。此类细菌有时被称为益生菌,并且人们已经提议在婴儿配方中加入适当的益生菌。
已经进行了广泛的研究以鉴定新的益生菌菌株。例如,EP 0199535,EP 0768375,WO 97/00078,EP 0577903和WO 00/53200公开了乳杆菌和双歧杆菌的特定菌株,以及它们有益的效果。
在一些国家中剖宫产比例持续增加,到达全部产婴的70%之多,因此,显然需要提供一种方法以降低风险,使剖宫产婴儿免受因其分娩方式而导致的不利健康后果的折磨。考虑到目前对选择剖宫产的孕妇常规给药预防剂量抗生素的做法,这样的需要尤为迫切。
发明概述
因此本发明提供了益生菌在制备用以预防或治疗剖宫产婴儿腹泻的药物或治疗性营养组合物中的用途。
本发明还扩展到降低剖宫产婴儿随后遭受腹泻发作的风险的方法,包括提供治疗量的益生菌给有此需要的剖宫产婴儿。
不希望受理论束缚,本发明人相信对剖宫产婴儿给药益生菌能够通过一些人们尚未完全了解的方式使婴儿胃肠道利于那些在健康、顺产婴儿中常见的双歧杆菌物种进行之后的建群,且这种有益的建群能够减少剖宫产婴儿腹泻发作(这样的发作使剖宫产婴儿备受折磨)的风险。应该指出,促进所施用益生菌本身的建群既不是这样的处理的目的,也不是其作用,而是为了促进与其他物种共同的建群,从而获得可与在健康、母乳喂养、顺产婴儿中所见的肠道微生物群相媲美的早期双歧杆菌肠道微生物群。
发明详述
在本说明书中,下列术语具有下列含意:
“早期双歧杆菌肠道菌群”是指对于年龄最高达12个月的婴儿,由双歧杆菌例如短双歧杆菌(Bifidobacterium breve)、婴儿双歧杆菌(Bifidobacterium infantis)和长双歧杆菌占优势的肠道菌群,其中排除了这些种类例如梭菌(Clostridia)和链球菌(Streptococci)的可观种群,这样的肠道菌群一般与在顺产、母乳喂养的同龄婴儿中所见的相当。
“婴儿”是指年龄在12个月以下的儿童。
“益生元(prebiotic)”是指一种不消化的食品成分,其通过选择性刺激结肠中一种或有限数量细菌的生长和/或活性,对宿主产生有利的影响,从而增加宿主健康。(Gibson and Roberfroid“Dietary Modulationof the Human Colonic Microbiota:Introducing the Concept ofPrebiotics”J.Nutr 125:1401-1412)。
“益生菌”是指对宿主的健康或良好状态具有有益作用的微生物细胞制剂或微生物细胞组分。(Salminen S,Ouwehand A.Benno Y.等″Probiotics:how should they be defined″Trends Food Sci.Technol.1999:10 107-10)。
除非另有说明,所有涉及的百分数都是重量百分数。
益生性细菌可以是任何具有确定的益生特性、并能够促进早期双歧杆菌肠道菌群发展的乳酸菌或双歧杆菌。合适的益生性乳酸菌包括鼠李糖乳杆菌(Lactobacillus rhamnosus)ATCC 53103,其与其它产品可以LGG商标从芬兰的Valio Oy获得,从Biogaia获得的鼠李糖乳杆菌(Lactobacillus rhamnosus)CGMCC 1.3724、路氏乳杆菌(Lactobacillusreuteri)ATCC 55730,发酵乳杆菌(Lactobacillus fermentum)VRI 003和副干酪乳杆菌(Lactobacillus paracasei)CNCM I-2116。
适宜的益生菌双歧杆菌菌株还包括日本莫里塔乳公司(Morinaga MilkIndustry Co.Ltd)出售的商标为BB536的长双歧杆菌ATCC BAA-999,Danisco出售的商标为Bb-03的短双歧杆菌菌株,Morinaga出售的商标为M-16V的短双歧杆菌菌株,Institut Rosell(Lallemand)出售的商标为R0070的短双歧杆菌菌株。乳酸菌和双歧杆菌的混合物也可使用。
合适的益生性细菌的每日剂量是105至1011集落形成单位(cfu),更优选的是107至1010cfu。
优选的同时施用益生菌和益生元。适合的益生元包括某些寡糖,例如寡聚果糖(FOS)和寡聚半乳糖(GOS)。可能使用益生元的组合,例如90%GOS和10%短链寡聚果糖(例如商标为Raftilose的产品)或10%菊粉(例如商标为Raftiline的产品)。
特别优选的,益生元为包括5-70wt%至少一种N-乙酰化寡糖、20-90wt%至少一种中性寡糖、5-50wt%至少一种唾液酸化寡糖的寡糖混合物,其中所述N-乙酰化寡糖选自GalNAcα1,3Galβ1,4Glc和Galβ1,6GalNAcα1,3Galβ1,4Glc,所述中性寡糖选自Galβ1,6Gal、Galβ1,6Galβ1,4Glc、Galβ1,6Galβ1,6Glc、Galβ1,3Galβ1,3Glc、Galβ1,3Galβ1,4Glc、Galβ1,6Galβ1,6Galβ1,4Glc、Galβ1,6Galβ1,3Galβ1,4Glc、Galβ1,3Galβ1,6Galβ1,4Glc和Galβ1,3Galβ1,3Galβ1,4Glc,所述唾液酸化寡糖选自NeuAcα2,3Galβ1,4Glc和NeuAcα2,6Galβ1,4Glc。这种寡糖混合物在WO2007/090894中有更详细的描述,其内容通过引入纳入本文,并且以下简称为“上述寡糖混合物”。
优选的,上述寡糖混合物包括10-70wt%特定的N-乙酰化寡糖,20-80wt%特定的中性寡糖和10-50wt%特定的唾液酸化寡糖。更优选的,混合物包括15-40wt%N-乙酰化寡糖,40-60wt%所述中性寡糖和15-30wt%唾液酸化寡糖。特别优选的,混合物包括30wt%N-乙酰化寡糖,50wt%中性寡糖和20wt%唾液酸化寡糖。
可选的,上述寡糖混合物可以方便的包括5-20wt%特定的N-乙酰化寡糖,60-90wt%特定的中性寡糖和5-30wt%特定的唾液酸化寡糖。
上述寡糖混合物可以从一种或多种动物乳中制备。其中动物乳可以从任何哺乳动物中获得,特别是从奶牛、山羊、水牛、马、大象、骆驼或绵羊中获得。
可选的,上述寡糖混合物可以通过购买和混合单个成分制备。例如,合成的寡聚半乳糖,如商标为Vivinal和Elix’或Elix的Galβ1,6Galβ1,4Glc、Galβ1,6Galβ1,6Glc、Galβ1,3Galβ1,4Glc、Galβ1,6Galβ1,6Galβ1,4Glc、Galβ1,6Galβ1,3Galβ1,4Glc和Galβ1,3Galβ1,6Galβ1,4Glc及其混合物是可商购的。其他的寡糖供应商是德斯克实验室(Dextra Laboratories)、西格马-阿尔德里克化学公司Sigma-AldrichChemie GmbH)和可瓦哈克公司(Kyowa Hakko Kogyo Co.,Ltd)。可选的,可使用特定的糖基转移酶(glycoslytransferase)如半乳糖基转移酶来生产中性寡糖。
N-乙酰化寡糖可通过氨基葡萄糖苷酶和/或氨基半乳糖苷酶对N-乙酰基-葡萄糖和/或N-乙酰基半乳糖的作用来制备。相同的,N-乙酰基-半乳糖基转移酶和/或N-乙酰基-糖基转移酶也可以用于该目的。N-乙酰化寡糖还可以通过使用相应的酶(重组的或天然的)的发酵技术和/或微生物发酵来生产。在后一种情况下,微生物可以表达它们天然的酶和底物,或者可以被改造为生产相应的底物和酶。可以使用单个微生物培养物或混合培养物。从DP=1起始的任何聚合度(DP)开始,可以通过受体底物开始N-乙酰化寡糖的形成。另一个选择是将游离或与寡糖(例如乳果糖)结合的己酮糖(例如果糖)化学转换为N-乙酰己糖胺或含有寡糖的N-乙酰己糖胺,如Wrodnigg,T.M.;Stutz,A.E.(1999)Angew.Chem.Int.Ed.38:827-828所描述的。
唾液酸化的寡糖3’唾液酸-乳糖和6’唾液酸-乳糖可以通过色谱或过滤技术从天然来源例如动物乳中分离。可选的,它们还可以通过使用特定唾液酸转移酶的生物技术来生产,所述生物技术是基于酶的发酵技术(重组或天然的酶)或微生物发酵技术。在后一种情况下,微生物可以表达它们天然的酶和底物,或者可以被改造为生产相应的底物和酶。可以使用单个微生物培养物或混合培养物。从DP=1起始的任何聚合度(DP)开始,可以通过受体底物开始唾液酸-寡糖的形成。
益生菌优选在婴儿出生后立即给药,并在此后的婴儿生命中的至少头两个月里给药。更优选的,给药持续到婴儿达6个月大。
益生菌可以直接对婴儿给药,或者,如果母亲进行哺乳,可以通过母亲给药。如果通过母亲给药,其可以作为一种补剂,例如可以是片剂、胶囊剂、锭剂、口香糖或液体形式。该补剂还可以包含保护性的水状胶体(如树胶、蛋白质、变性淀粉)、粘合剂、薄膜形成剂、成胶囊剂/成胶囊材料、(囊)壁材料(wall material)/壳体材料(shell material)、基质化合物、包衣、乳化剂、表面活性剂、增溶剂(油、脂肪、蜡、卵磷脂等)、吸附剂、载体、填料、复方(co-compound)、分散剂、润湿剂、加工助剂(溶剂)、流动助剂(flowing agent)、掩味剂(taste masking agent)、增重剂、胶凝剂(jellifying agent)、凝胶形成剂(gel forming agent)、抗氧化剂和抗菌剂。该补剂也可以包含常规的药物添加剂和佐剂、赋形剂和稀释剂,包括但不限于水、任何来源的明胶、植物胶、木素磺酸盐、滑石、糖、淀粉、阿拉伯胶、植物油、聚亚烷基二醇、调味剂、防腐剂、稳定剂、乳化剂、缓冲液、润滑剂、着色剂、湿润剂、填充剂等等。在所有情况下,会视其是否适合预期接受者选择像这样的其他组分。
可选的,益生菌可以以治疗性营养组合物的形式向母亲给药。该组合物可为全面营养配方。
本发明所述的向哺乳期妇女给药的全面营养配方可以包含蛋白质来源。可以使用任何合适的食用蛋白质,例如动物蛋白质(比如乳蛋白质、肉类蛋白质和卵蛋白质);植物蛋白质(比如大豆蛋白质、小麦蛋白质、水稻蛋白质和豌豆蛋白质);游离氨基酸混合物;或其组合。乳蛋白质比如酪蛋白和乳清,及大豆蛋白质是特别优选的。组合物还可以包含碳水化合物来源和脂肪来源。
如果配方还包括DHA以外的脂肪来源,则该脂肪来源优选提供该配方能量的5%至40%;例如该配方能量的20%至30%。使用低芥酸菜子油、玉米油和高油酸的葵花籽油的混合物,可以获得合适的脂肪谱(fatprofile)。
可将碳水化合物来源添加到该配方中。其优选提供该配方能量的40%至80%。可以使用任何合适的碳水化合物,例如蔗糖、乳糖、葡萄糖、果糖、玉米糖浆固体、麦芽糖糊精、及其混合物。如果期望也可以加入膳食纤维。未经酶消化的膳食纤维从小肠通过,并起天然膨胀剂和缓泻药的作用。膳食纤维可以是可溶或不溶的,一般优选两种类型的混合物。合适的膳食纤维来源包括大豆、豌豆、燕麦、果胶、瓜尔胶、阿拉伯胶、寡聚果糖和寡聚半乳糖。优选地,如果存在纤维,则摄入的纤维含量是该配方的2至40g/l之间,更优选是4至10g/l之间。此外,配方也优选包含数量为每升重构配方0.2至5克的上述寡糖混合物,优选1至2g/l。
根据政府团体如USRDA的推荐,该配方还可以包含矿物质和微量营养素如微量元素和维生素。例如,每日剂量中该配方可以按所给出的范围包含一种或多种以下微量营养素:300至500mg钙,50至100mg镁,150至250mg磷,5至20mg铁,1至7mg锌,0.1至0.3mg铜,50至200μg碘,5至15μg硒,1000至3000μg β-胡萝卜素,10至80mg维生素C,1至2mg维生素B1,0.5至1.5mg维生素B6,0.5至2mg维生素B2,5至18mg烟酸,0.5至2.0μg维生素B12,100至800μg叶酸,30至70μg生物素,1至5μg维生素D,3至10IU维生素E。
如果期望,可以将一种或更多种食品级的乳化剂掺入到该配方中;例如双乙酰酒石酸单甘油酯和双乙酰酒石酸双甘油酯、卵磷脂以及单甘油酯和双甘油酯。同样可以包括合适的盐和稳定剂。
该配方优选可肠内给药;例如用于以乳或水重构的粉剂形式。
可选的,或是对于不使用母乳喂养的婴儿来说,益生菌可以作为补剂给药于婴儿,例如以日剂量1010 cfu溶解在水中用汤匙施用。
对于不使用母乳喂养的婴儿,益生菌可以在婴儿配方中很方便的给药。
根据本发明使用的婴儿配方可以包含含量不多于2.0g/100kcal的蛋白质来源,优选1.8至2.0g/100kcal。尽管优选超过50%(以重量计)的蛋白质来源是乳清,但只要满足必需氨基酸含量的最低要求且保证令人满意的生长,相信蛋白质的类型对于本发明并非关键。因此,可以使用基于乳清、酪蛋白及其混合物的蛋白质来源,也可以使用基于大豆的蛋白质来源。只要涉及乳清蛋白质,该蛋白质来源可以基于酸乳清或甜乳清或其混合物,且可以依期望包括任何比例的α-乳清蛋白和β-乳球蛋白。
蛋白质可以是完整的或水解的、或完整和水解蛋白质的混合物。可能期望提供部分水解的蛋白质(水解程度在2%至20%之间),例如供给被认为有产生牛奶过敏风险的婴儿。如果需要水解的蛋白质,则水解过程可以按期望和按本领域所已知的进行。例如,乳清蛋白质水解物可以通过在一个或更多步骤中酶水解乳清组分而制备。如果用作起始材料的乳清组分实质上没有乳糖,则发现在水解过程中,蛋白质经受少得多的赖氨酸阻碍(lysine blockage)。这能使赖氨酸阻碍的程度从总赖氨酸重量的约15%减少到少于赖氨酸重量的约10%;例如赖氨酸重量的约7%,其大为改善蛋白质来源的营养质量。
婴儿配方可以包含碳水化合物来源。虽然优选的碳水化合物来源是乳糖,但是在婴儿配方中通常见到的任何碳水化合物来源如乳糖、蔗糖、麦芽糖糊精、淀粉及其混合物都可以使用。优选地,碳水化合物来源提供配方总能量的35%至65%。
婴儿配方可以包含脂质来源。脂质来源可以是任何适合用于婴儿配方的脂质或脂肪。优选的脂肪来源包括棕榈油酸甘油酯、高油酸葵花籽油和高油酸红花油。还可以添加必需脂肪酸亚油酸和α-亚麻酸,同样可以添加少量油类,所述油类包含大量预先形成的花生四烯酸和二十二碳六烯酸如鱼油或微生物油。总体上,脂肪含量优选比如提供配方总能量的30%至55%之间。脂肪来源优选具有n-6与n-3脂肪酸的比值为约5∶1至约15∶1;例如为约8∶1至约10∶1。
婴儿配方还可以包含人们认为是每日饮食中所必需的所有维生素和矿物质,且以营养上有效的量包含这些维生素和矿物质。对于某些维生素和矿物质已经确立了最低需求。任选地存在于婴儿配方中的矿物质、维生素和其它营养素的例子包括维生素A、维生素B1、维生素B2、维生素B6、维生素B12、维生素E、维生素K、维生素C、维生素D、叶酸、肌醇、烟酸、生物素、泛酸、胆碱、钙、磷、碘、铁、镁、铜、锌、锰、氯化物、钾、钠、硒、铬、钼、牛磺酸和L-肉碱。矿物质通常以盐形式添加。特定矿物质和其它维生素的存在和含量将依据预期的婴儿群体而改变。
如果需要,婴儿配方可以包含乳化剂和稳定剂,比如大豆卵磷脂、柠檬酸单甘油酯和柠檬酸双甘油酯等。
优选的,婴儿配方中将包含上述寡糖混合物,数量为每升重构配方中0.2至5克,优选1至2克/升。
婴儿配方可以任选地包含其它可能具有有益作用的物质,比如乳铁蛋白、核苷酸、核苷等。
上述的婴儿配方和营养配方都可以用任何合适的方式制备。例如,它们可以通过将蛋白质、碳水化合物来源和脂肪来源以适当的比例混合在一起而制备。如果使用乳化剂,则在此时可以包括乳化剂。在此时可以加入维生素和矿物质,但通常之后加入以避免热降解。任何亲脂性维生素、乳化剂等可以在混合之前溶解在脂肪来源中。然后可将水(优选已经过反渗透的水)混合进去形成液体混合物。合宜的水温为约50℃至约80℃以帮助成分的分散。可以使用可商购的液化器形成液体混合物。然后将液体混合物均质化;例如分两个阶段进行。
然后,例如通过迅速地加热该液体混合物至温度范围为约80℃至约150℃约5秒钟至约5分钟,可将液体混合物热处理以减少细菌数量。这可以通过蒸汽注入、高压灭菌或通过热交换器例如板式热交换器进行。
然后,该液体混合物可以冷却(例如通过瞬时冷却)至约60℃至约85℃。然后可将液体混合物再次均质化;例如分两个阶段,第一个阶段中约为10MPa至约30MPa,第二个阶段中约为2MPa至约10MPa。然后可以将均质化的混合物进一步冷却以加入任何热敏感组分;比如维生素和矿物质。此时可方便地调整均质化的混合物的pH和固形物含量。
将均质化的混合物转移至合适的干燥装置比如喷雾干燥器或冷冻干燥器,并转化成粉末。该粉末的含湿量以重量计应该少于约5%。
选中的益生菌可以根据任何适宜的方法培养,并通过例如冻干或喷雾干燥制备以添加到营养配方或婴儿配方中。可选的,细菌制剂可以为从专门供应商Christian Hansen和Valio购买的产品,购得时已经制备成用于添加至食品(如营养配方和婴儿配方)的合适形式。益生菌可以以103至1012cfu/g粉末的数量加入到配方中,更优选的为107至1012cfu/g粉末。
本发明将通过参考下列实施例进一步举例说明:
实施例1
下面给出在本发明中使用的合适的婴儿配方的组成的例子:
Claims (15)
1.益生菌在制备用以预防或治疗剖宫产婴儿腹泻的药物或治疗性营养组合物中的用途。
2.根据权利要求1的用途,其中益生菌为乳酸菌。
3.根据权利要求2的用途,其中乳酸菌菌株为鼠李糖乳杆菌ATCC53103、鼠李糖乳杆菌CGMCC 1.3724、路氏乳杆菌ATCC 55730、发酵乳杆菌VRI 003或副干酪乳杆菌CNCM I-2116。
4.根据权利要求1的用途,其中益生菌为双歧杆菌。
5.根据权利要求4的用途,其中双歧杆菌菌株为长双歧杆菌ATCCBAA-999、短双歧杆菌Bb-03、短双歧杆菌M-16V或短双歧杆菌R0070。
6.根据前述权利要求任一项所述的用途,其中药物或治疗性营养组合物还包括寡糖混合物,所述寡糖混合物包括5-70wt%至少一种N-乙酰化寡糖、20-90wt%至少一种中性寡糖、5-50wt%至少一种唾液酸化寡糖,其中所述N-乙酰化寡糖选自GalNAcα1,3Galβ1,4Glc和Galβ1,6GalNAcα1,3Galβ1,4Glc,所述中性寡糖选自Galβ1,6Gal、Galβ1,6Galβ1,4Glc、Galβ1,6Galβ1,6Glc、Galβ1,3Galβ1,3Glc、Galβ1,3Galβ1,4Glc、Galβ1,6Galβ1,6Galβ1,4Glc、Galβ1,6Galβ1,3Galβ1,4Glc、Galβ1,3Galβ1,6Galβ1,4Glc和Galβ1,3Galβ1,3Galβ1,4Glc,所述唾液酸化寡糖选自NeuAcα2,3Galβ1,4Glc和NeuAcα2,6Galβ1,4Glc。
7.根据权利要求6所述的用途,其中寡糖混合物包括10-70wt%的N-乙酰化寡糖,20-80wt%的中性寡糖和10-50wt%的唾液酸化寡糖。
8.根据权利要求6或7所述的用途,其中寡糖混合物包括15-40wt%的N-乙酰化寡糖,40-60wt%的中性寡糖和15-30wt%的唾液酸化寡糖。
9.根据权利要求6或7所述的用途,其中寡糖混合物包括5-20wt%的N-乙酰化寡糖,60-90wt%的中性寡糖和5-30wt%的唾液酸化寡糖。
10.根据上述任一项权利要求中所述的用途,其中药物或治疗性营养组合物在婴儿出生后立即向婴儿给药,以及在此后的至少两个月里向婴儿给药。
11.根据上述任一项权利要求中所述的用途,其中药物或治疗性营养组合物在婴儿出生后的至少6个月中向婴儿给药。
12.根据上述任一项权利要求中所述的用途,其中益生菌通过母乳喂养的母亲向婴儿给药。
13.根据权利要求1-11中任一项所述的用途,其中治疗性营养组合物是婴儿配方。
14.根据上述任一项权利要求中所述的用途,其中药物的每日剂量中包括105到1011cfu的益生菌。
15.根据权利要求1-13中任一项所述的用途,其中治疗性营养组合物的每克组合物(干重)中包括103到1012cfu的益生菌。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07105074.4 | 2007-03-28 | ||
EP07105074A EP1974743A1 (en) | 2007-03-28 | 2007-03-28 | Probiotics to Improve Gut Microbiota |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101646452A true CN101646452A (zh) | 2010-02-10 |
Family
ID=38051788
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880010593A Pending CN101646453A (zh) | 2007-03-28 | 2008-03-27 | 改善肠道小型生物群的合益素 |
CN200880010514A Pending CN101652080A (zh) | 2007-03-28 | 2008-03-27 | 使用益生菌改善肠道微生物群 |
CN200880009758A Pending CN101652079A (zh) | 2007-03-28 | 2008-03-27 | 减少剖腹产出生的婴儿中过敏症发生的益生菌 |
CN200880010523A Pending CN101646452A (zh) | 2007-03-28 | 2008-03-27 | 使用益生菌降低剖宫产婴儿的腹泻发作 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880010593A Pending CN101646453A (zh) | 2007-03-28 | 2008-03-27 | 改善肠道小型生物群的合益素 |
CN200880010514A Pending CN101652080A (zh) | 2007-03-28 | 2008-03-27 | 使用益生菌改善肠道微生物群 |
CN200880009758A Pending CN101652079A (zh) | 2007-03-28 | 2008-03-27 | 减少剖腹产出生的婴儿中过敏症发生的益生菌 |
Country Status (15)
Country | Link |
---|---|
US (4) | US20100119497A1 (zh) |
EP (6) | EP1974743A1 (zh) |
CN (4) | CN101646453A (zh) |
AU (4) | AU2008231702B2 (zh) |
BR (4) | BRPI0809626A2 (zh) |
CA (4) | CA2682654A1 (zh) |
ES (2) | ES2434566T3 (zh) |
MX (4) | MX337667B (zh) |
MY (1) | MY151137A (zh) |
PL (2) | PL2131680T3 (zh) |
PT (2) | PT2131680E (zh) |
RU (4) | RU2009139667A (zh) |
UA (2) | UA97663C2 (zh) |
WO (4) | WO2008116892A1 (zh) |
ZA (3) | ZA200907541B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108935698A (zh) * | 2018-09-11 | 2018-12-07 | 内蒙古伊利实业集团股份有限公司 | 一种预防小儿腹泻疾病的营养组合物及应用 |
CN111053244A (zh) * | 2019-12-06 | 2020-04-24 | 山东体育学院 | 一种基于肠道微生物的营养调节方法及系统 |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
BRPI0708689A2 (pt) | 2006-03-07 | 2011-06-07 | Nestec Sa | mistura simbiótica |
RU2445361C2 (ru) * | 2006-06-13 | 2012-03-20 | Нестек С.А. | Профилактика и лечение воспаления среднего уха с помощью непатогенных штаммов бактерий |
EP2147678A1 (en) * | 2008-07-21 | 2010-01-27 | Nestec S.A. | Probiotics to increase IgA secretion in infants born by caesarean section |
US8498729B2 (en) | 2008-08-29 | 2013-07-30 | Smp Logic Systems Llc | Manufacturing execution system for use in manufacturing baby formula |
WO2010063601A1 (en) * | 2008-12-05 | 2010-06-10 | Nestec S.A. | Compositions for use in low-birth weight infants |
EP2206506A1 (en) * | 2008-12-18 | 2010-07-14 | Bracco Imaging S.p.A | Probiotic formulations |
WO2010103132A1 (es) * | 2009-03-10 | 2010-09-16 | Hero España, S.A. | Aislamiento, identificación y caracterización de cepas con actividad probiótica a partir de heces de lactantes alimentados exclusivamente con leche materna |
CA2767960A1 (en) * | 2009-07-31 | 2011-02-03 | Nestec S.A. | Nutritional composition for breast-fed infants or pets with probiotics and selected nutrients |
EP2289527B1 (en) | 2009-08-25 | 2018-02-21 | Nestec S.A. | Bifidobacterium longum and functional GI disorders |
WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性t細胞の増殖または集積を誘導する作用を有する組成物 |
EP2452575A1 (en) * | 2010-11-15 | 2012-05-16 | Nestec S.A. | Array of age-tailored nutritional formula with probiotics |
EP2465507A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Oligosaccharide composition for treating skin diseases |
EP2455387A1 (en) | 2010-11-23 | 2012-05-23 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
EP2658559A1 (en) * | 2010-12-29 | 2013-11-06 | Nestec S.A. | Fiber and probiotics for reducing intestinal symptoms related to stress |
EE05721B1 (et) | 2011-02-25 | 2014-08-15 | OÜ Tervisliku Piima Biotehnoloogiate Arenduskeskus | Isoleeritud mikroorganismi tüvi L. plantarum MCC1 DSM 23881 ja selle kasutamine |
EP2510932A1 (en) * | 2011-04-15 | 2012-10-17 | Nestec S.A. | Lactobacillus paracasei NCC2461 (ST11) for use by perinatal maternal administration in the reduction and prevention of allergies in progeny |
JP2014516589A (ja) | 2011-06-20 | 2014-07-17 | エイチ.ジェイ.ハインツ カンパニー | プロバイオティック組成物及び方法(probioticcompositionandmethods) |
JP5877902B2 (ja) | 2011-08-17 | 2016-03-08 | マイクロバイオーム セラピューティクス,エルエルシー | バクテロイデス門の胃腸管微生物相対フィルミクテス門の微生物相の比を上昇させるための組成物および製剤の使用 |
ES2546262T5 (es) * | 2011-10-18 | 2019-04-12 | Nestec Sa | Composición para emplear en la promoción de la absorción del magnesio y/o la retención del magnesio |
CA2892588A1 (en) | 2011-12-01 | 2013-06-06 | School Corporation, Azabu Veterinary Medicine Educational Institution | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
JP6115094B2 (ja) * | 2012-11-15 | 2017-04-19 | 株式会社Gsユアサ | 蓄電素子及び蓄電素子の製造方法 |
BR112015028164B1 (pt) | 2013-05-10 | 2022-02-08 | H.J. Heinz Company Brands Llc | Usos da bactéria probiótica, lactobacillus paracasei, para tratar uma infecção microbiana e para prevenir ou reduzir a gravidade de uma infecção microbiana |
US11135232B2 (en) | 2013-11-15 | 2021-10-05 | Societe Des Produits Nestle S.A. | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children |
MX2016006220A (es) | 2013-11-15 | 2016-08-08 | Nestec Sa | Composiciones para usar en la prevencion o tratamiento de la enterocolitis necrotizante en infantes y niños pequeños nacidos por cesarea. |
US10758555B2 (en) | 2013-11-15 | 2020-09-01 | Societe Des Produits Nestle S.A. | Compositions for preventing or treating allergies in infants from or fed by non secretor mothers by providing fucosylated-oligosaccharides in particular among infants at risk or born by C-section |
MX2016006060A (es) * | 2013-11-15 | 2016-08-03 | Nestec Sa | Composiciones para usar en la prevencion o tratamiento de la enterocolitis necrotizante en infantes y niños pequeños. |
KR20170072879A (ko) | 2014-10-29 | 2017-06-27 | 네스텍 소시에테아노님 | 생애 초기에 미생물총 불균형을 회복하기 위한 l. 루테리의 용도 |
EP3294308A4 (en) | 2015-05-14 | 2019-03-06 | University of Puerto Rico | PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN |
AU2016303003A1 (en) * | 2015-08-04 | 2017-12-07 | Société des Produits Nestlé S.A. | Nutritional compositions and infant formulas comprising Bifidobacterium animalis ssp. lactis and optionally a mix of oligosaccharides for inducing a gut microbiota close to the one of breast fed infants |
WO2017043963A1 (en) * | 2015-09-11 | 2017-03-16 | N.V. Nutricia | Kit of parts for stimulating microbiota health after non-natural birth |
US11564667B2 (en) | 2015-12-28 | 2023-01-31 | New York University | Device and method of restoring microbiota of newborns |
US11229659B2 (en) | 2016-01-26 | 2022-01-25 | Societe Des Produits Nestle S.A. | Compositions with specific oligosaccharides to prevent or treat allergies |
EP3466435B1 (en) * | 2016-05-31 | 2023-08-16 | Morinaga Milk Industry Co., Ltd. | Brain function improving agent |
US20180030403A1 (en) | 2016-07-28 | 2018-02-01 | Bobban Subhadra | Devices, systems and methods for the production of humanized gut commensal microbiota |
EP3493686B1 (en) * | 2016-08-04 | 2024-03-27 | Société des Produits Nestlé S.A. | Nutritional compositions and infant formulas comprising a mix of oligosaccharides and optionally bifidobacterium lactis for preventing, treating or reducing the severity of non-rotavirus-associated diarrhoea |
MX2019013143A (es) * | 2017-05-05 | 2020-07-14 | Nestle Sa | Tratamiento de colicos infantiles. |
EP3661371A1 (en) * | 2017-08-04 | 2020-06-10 | Société des Produits Nestlé S.A. | Probiotic bacteria preconditioned in a gos-containing medium and use thereof |
CN113164532A (zh) * | 2018-05-30 | 2021-07-23 | 进化生物系统股份有限公司 | H5功能性长双歧杆菌婴儿亚种的组合物和使用方法 |
CN109497271A (zh) * | 2018-12-06 | 2019-03-22 | 江苏奥迈生物科技有限公司 | 一种提高断奶仔猪免疫力的复合饲料添加剂及其制备方法 |
WO2020251249A1 (ko) * | 2019-06-11 | 2020-12-17 | 주식회사 천랩 | 영유아의 장내 미생물 불균형도를 탐지하는 방법 |
TWI754302B (zh) * | 2019-06-21 | 2022-02-01 | 大江生醫股份有限公司 | 乳雙歧桿菌tci604及其代謝產物的應用 |
CN111296711A (zh) * | 2020-03-31 | 2020-06-19 | 广州纽缤乐营养科技股份有限公司 | 一种益生菌固体饮料及其制备方法 |
WO2023237679A1 (en) * | 2022-06-10 | 2023-12-14 | Dsm Ip Assets B.V. | Combinations comprising vitamin b2 and lactobacillus rhamnosus |
WO2023237687A1 (en) * | 2022-06-10 | 2023-12-14 | Dsm Ip Assets B.V. | Combinations comprising vitamin b2 and lactobacillus rhamnosus |
WO2024105265A1 (fr) | 2022-11-17 | 2024-05-23 | Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement | Limosilactobacillus mucosae et désordres nécessitant un accroissement du niveau de glp-1 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4839281A (en) | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
SU1743607A1 (ru) * | 1990-02-05 | 1992-06-30 | 2-й Московский государственный медицинский институт им.Н.И.Пирогова | Способ профилактики дисбактериоза кишечника у новорожденных детей |
EP0577903B1 (fr) | 1992-07-06 | 1997-12-17 | Societe Des Produits Nestle S.A. | Agent antigastrite |
DK0768375T4 (da) * | 1992-07-06 | 2002-09-16 | Nestle Sa | Mælkesyrebakterier |
FI104465B (fi) | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
NL1010770C2 (nl) * | 1998-12-09 | 2000-06-13 | Nutricia Nv | Preparaat dat oligosacchariden en probiotica bevat. |
EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
DE19958985A1 (de) * | 1999-12-07 | 2001-06-13 | Nutricia Nv | Oligosaccharidmischung |
FI110668B (fi) * | 2000-06-20 | 2003-03-14 | Aboatech Ab Oy | Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn |
WO2005000748A1 (en) | 2003-06-27 | 2005-01-06 | Bio-Circuit Aps | A biogas producing facility with anaerobic hydrolysis |
MX2007012697A (es) * | 2005-04-13 | 2008-01-14 | Nestec Sa | Formula para infantes con probioticos. |
EP1776877A1 (en) * | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
PL1988786T3 (pl) * | 2006-02-10 | 2010-10-29 | Nestec Sa | Mieszanka oligosacharydowa |
BRPI0708689A2 (pt) * | 2006-03-07 | 2011-06-07 | Nestec Sa | mistura simbiótica |
RU2445361C2 (ru) * | 2006-06-13 | 2012-03-20 | Нестек С.А. | Профилактика и лечение воспаления среднего уха с помощью непатогенных штаммов бактерий |
-
2007
- 2007-03-28 EP EP07105074A patent/EP1974743A1/en not_active Withdrawn
-
2008
- 2008-03-27 CA CA002682654A patent/CA2682654A1/en not_active Abandoned
- 2008-03-27 RU RU2009139667/13A patent/RU2009139667A/ru unknown
- 2008-03-27 AU AU2008231702A patent/AU2008231702B2/en not_active Ceased
- 2008-03-27 WO PCT/EP2008/053611 patent/WO2008116892A1/en active Application Filing
- 2008-03-27 PL PL08735504T patent/PL2131680T3/pl unknown
- 2008-03-27 CN CN200880010593A patent/CN101646453A/zh active Pending
- 2008-03-27 CA CA002680093A patent/CA2680093A1/en not_active Abandoned
- 2008-03-27 MY MYPI20093396 patent/MY151137A/en unknown
- 2008-03-27 UA UAA200910897A patent/UA97663C2/ru unknown
- 2008-03-27 BR BRPI0809626-0A patent/BRPI0809626A2/pt not_active IP Right Cessation
- 2008-03-27 CA CA002679081A patent/CA2679081A1/en not_active Abandoned
- 2008-03-27 CN CN200880010514A patent/CN101652080A/zh active Pending
- 2008-03-27 RU RU2009139669/15A patent/RU2456008C2/ru not_active IP Right Cessation
- 2008-03-27 RU RU2009139658/10A patent/RU2521500C2/ru active
- 2008-03-27 BR BRPI0809356-3A patent/BRPI0809356A2/pt not_active IP Right Cessation
- 2008-03-27 US US12/593,457 patent/US20100119497A1/en not_active Abandoned
- 2008-03-27 WO PCT/EP2008/053661 patent/WO2008116916A1/en active Application Filing
- 2008-03-27 UA UAA200910896A patent/UA97662C2/ru unknown
- 2008-03-27 EP EP08718275A patent/EP2129242A1/en not_active Withdrawn
- 2008-03-27 ES ES08735504T patent/ES2434566T3/es active Active
- 2008-03-27 ES ES08718285.3T patent/ES2577434T3/es active Active
- 2008-03-27 MX MX2009010252A patent/MX337667B/es active IP Right Grant
- 2008-03-27 EP EP08718285.3A patent/EP2131859B1/en active Active
- 2008-03-27 WO PCT/EP2008/053638 patent/WO2008116904A1/en active Application Filing
- 2008-03-27 MX MX2009009931A patent/MX2009009931A/es not_active Application Discontinuation
- 2008-03-27 CA CA002678994A patent/CA2678994A1/en not_active Abandoned
- 2008-03-27 CN CN200880009758A patent/CN101652079A/zh active Pending
- 2008-03-27 WO PCT/EP2008/053644 patent/WO2008116907A1/en active Application Filing
- 2008-03-27 PL PL08718285.3T patent/PL2131859T3/pl unknown
- 2008-03-27 PT PT87355046T patent/PT2131680E/pt unknown
- 2008-03-27 BR BRPI0809355-5A patent/BRPI0809355A2/pt not_active IP Right Cessation
- 2008-03-27 MX MX2009009318A patent/MX2009009318A/es not_active Application Discontinuation
- 2008-03-27 CN CN200880010523A patent/CN101646452A/zh active Pending
- 2008-03-27 US US12/593,462 patent/US20100119488A1/en not_active Abandoned
- 2008-03-27 EP EP08735504.6A patent/EP2131680B1/en active Active
- 2008-03-27 PT PT87182853T patent/PT2131859T/pt unknown
- 2008-03-27 US US12/532,021 patent/US20100086527A1/en not_active Abandoned
- 2008-03-27 RU RU2009139660/15A patent/RU2009139660A/ru not_active Application Discontinuation
- 2008-03-27 AU AU2008231778A patent/AU2008231778A1/en not_active Abandoned
- 2008-03-27 AU AU2008231763A patent/AU2008231763B2/en active Active
- 2008-03-27 BR BRPI0809622-8A patent/BRPI0809622A2/pt not_active Application Discontinuation
- 2008-03-27 MX MX2009009442A patent/MX2009009442A/es active IP Right Grant
- 2008-03-27 US US12/532,056 patent/US20100150874A1/en not_active Abandoned
- 2008-03-27 EP EP12164144.3A patent/EP2489280A3/en not_active Withdrawn
- 2008-03-27 AU AU2008231775A patent/AU2008231775A1/en not_active Abandoned
- 2008-03-27 EP EP08718272A patent/EP2129393A1/en not_active Withdrawn
-
2009
- 2009-10-27 ZA ZA2009/07541A patent/ZA200907541B/en unknown
- 2009-10-27 ZA ZA2009/07731A patent/ZA200907731B/en unknown
- 2009-10-27 ZA ZA2009/07538A patent/ZA200907538B/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108935698A (zh) * | 2018-09-11 | 2018-12-07 | 内蒙古伊利实业集团股份有限公司 | 一种预防小儿腹泻疾病的营养组合物及应用 |
CN111053244A (zh) * | 2019-12-06 | 2020-04-24 | 山东体育学院 | 一种基于肠道微生物的营养调节方法及系统 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101646452A (zh) | 使用益生菌降低剖宫产婴儿的腹泻发作 | |
CN102159226B (zh) | 增加剖宫产出生婴儿的IgA分泌的益生菌 | |
US11260067B2 (en) | Methods and compositions for decreasing concentrations of detrimental proteolytic metabolites, treating health disorders, and/or promoting health benefits in infants or young children | |
CN102065872A (zh) | 改善肠微生物群的益生菌 | |
EP2127661A1 (en) | Probiotics to improve gut microbiotica | |
CN107404925A (zh) | 用于预防或治疗婴儿或幼儿胃肠感染/炎症的组合物 | |
CN107404931A (zh) | 用于改善婴儿或幼儿粪便稠度或频率的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100210 |